Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Raw Materials: 2023-2024

Historic Raw Materials for Ligand Pharmaceuticals (LGND) over the last 1 years, with Dec 2024 value amounting to $603,000.

  • Ligand Pharmaceuticals' Raw Materials rose 43.57% to $603,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $603,000, marking a year-over-year increase of 43.57%. This contributed to the annual value of $603,000 for FY2024, which is 43.57% up from last year.
  • According to the latest figures from Q4 2024, Ligand Pharmaceuticals' Raw Materials is $603,000, which was down 75.83% from $2.5 million recorded in Q3 2024.
  • Ligand Pharmaceuticals' Raw Materials' 5-year high stood at $2.5 million during Q3 2024, with a 5-year trough of $420,000 in Q4 2023.
  • For the 2-year period, Ligand Pharmaceuticals' Raw Materials averaged around $1.3 million, with its median value being $1.0 million (2024).
  • Data for Ligand Pharmaceuticals' Raw Materials shows a peak YoY soared of 43.57% (in 2024) over the last 5 years.
  • Ligand Pharmaceuticals' Raw Materials (Quarterly) stood at $420,000 in 2023, then soared by 43.57% to $603,000 in 2024.
  • Its Raw Materials was $603,000 in Q4 2024, compared to $2.5 million in Q3 2024 and $1.5 million in Q2 2024.